北海康成-B(01228.HK)上涨11%，公司稍早公布折价近15%向药明生物子公司发行新股。

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228.HK) experienced an 11% increase in stock price following the announcement of a new share issuance at a nearly 15% discount to WuXi Biologics' subsidiary [1] Group 2 - The company is issuing new shares to a subsidiary of WuXi Biologics, indicating a strategic partnership or investment [1] - The discount of nearly 15% on the new shares suggests a significant valuation consideration in the transaction [1] - The stock price reaction of an 11% increase reflects positive market sentiment towards the company's decision [1]